The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Outcomes of Hodgkin lymphoma patients who receive a second ASCT
Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the latest EBMT Lymphoma Working Party registry study. This evaluated the outcome of relapsed/refractory Hodgkin lymphoma patients who received a second autologous stem cell transplantation (ASCT2). Dr Sureda highlights the key messages from this study; the time between transplants is the most important predictive factor for long-term outcomes.
